SAN DIEGO, June 3 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will be presenting at the Goldman Sachs Annual Global Health
Care Conference on Tuesday, June 9, 2009 at 10:45 a.m. ET / 7:45 a.m. PT in
New York. Daniel M. Bradbury, president and chief executive officer of Amylin
Pharmaceuticals, will provide a corporate overview.
The live presentation and breakout session will be webcast, and a
recording will be made available following the event. The webcast and
recording will be accessible through Amylin's corporate Web site, located at
www.amylin.com. To access the live webcast, please log on to Amylin's site
approximately fifteen minutes prior to the presentation to register and
download any necessary audio software.
About Amylin Pharmaceuticals
Amylin Pharmaceuticals is a biopharmaceutical company committed to
improving lives through the discovery, development and commercialization of
innovative medicines. Amylin has developed and gained approval for two
first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate)
injection and BYETTA(R) (exenatide) injection. Amylin's research and
development activities leverage the Company's expertise in metabolism to
develop potential therapies to treat diabetes and obesity. Amylin is
headquartered in San Diego, California. Further information about Amylin
Pharmaceuticals is available at www.amylin.com.
SOURCE Amylin Pharmaceuticals, Inc.
-0- 06/03/2009
/CONTACT: Michael York, Senior Director, Investor Relations of Amylin
Pharmaceuticals, Inc., +1-858-552-2200, ext. 8602/
/Web Site: http://www.amylin.com /
(AMLN)
